SCHEMBL6475423

SCHEMBL6475423

CCCCN(CCCC)c1ccc(CCc2ccc(Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
RECQL P46063 1/20 0.56
BLM P54132 1/20 0.56
KMT2A Q03164 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
SIRT2 Q8IXJ6 1/20 0.53
PLK1 P53350 4/20 0.51
PLK3 Q9H4B4 3/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
FABP4 P15090 1/20 0.48
TRPA1 O75762 1/20 0.46
TRPM2 O94759 1/20 0.46
PLA2G1B P04054 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.46
CYSLTR2 Q9NS75 1/20 0.46
CYSLTR1 Q9Y271 1/20 0.46
CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486359 0.97 PLK1 (0.53) MEN1RECQLBLMKMT2ATDP1
SCHEMBL27560781 0.93 MEN1 (0.58) MEN1RECQLBLMKMT2ATDP1
Hydrochloric Acid SCHEMBL6475141 0.92 MEN1 (0.57) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6482938 0.91 MEN1 (0.53) MEN1RECQLBLMKMT2ATDP1
SCHEMBL27560788 0.90 MEN1 (0.56) MEN1RECQLBLMKMT2ATDP1
Hydrochloric Acid SCHEMBL6474566 0.89 MEN1 (0.55) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6474259 0.88 MEN1 (0.60) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6474896 0.87 MEN1 (0.53) MEN1RECQLBLMKMT2ATDP1
SCHEMBL22452695 0.86 SIRT2 (0.55) MEN1KMT2ASIRT2PLK1PLK3
Hydrochloric Acid SCHEMBL6474052 0.86 MEN1 (0.58) MEN1RECQLBLMKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US claimed
CN-1378446-A Method for inhibiting amyloid aggregation and imaging amyloid deposits WARNER LAMBERT CO (US) 2002-11-06 CN claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
CN-1378446-A Method for inhibiting amyloid aggregation and imaging amyloid deposits WARNER LAMBERT CO (US) 2002-11-06 CN disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885RECQL 1257/4885BLM 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.